Meningioma: Molecular Updates from the 2021 World Health Organization Classification of CNS Tumors and Imaging Correlates

References

1. 1.↵
   1. Ostrom QT,
   2. Cioffi G,
   3. Gittleman H, et al

   . CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. Neuro Oncol 2019;21:v1–v100 doi:10.1093/neuonc/noz150 pmid:31675094

   CrossRefPubMed
2. 2.↵
   1. Serratrice N,
   2. Lameche I,
   3. Attieh C, et al

   . Spinal meningiomas, from biology to management: a literature review. Front Oncol 2023;12:1084404 doi:10.3389/fonc.2022.1084404 pmid:36713513

   CrossRefPubMed
3. 3.↵
   1. Elsamadicy AA,
   2. Reeves BC,
   3. Craft S, et al

   . A current review of spinal meningiomas: epidemiology, clinical presentation and management. J Neurooncol 2023;161:395–404 doi:10.1007/s11060-023-04238-1 pmid:36637710

   CrossRefPubMed
4. 4.↵
   1. Gritsch S,
   2. Batchelor TT,
   3. Gonzalez Castro LN

   . Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization Classification of Tumors of the Central Nervous System. Cancer 2022;128:47–58 doi:10.1002/cncr.33918 pmid:34633681

   CrossRefPubMed
5. 5.↵
   1. Goldbrunner R,
   2. Stavrinou P,
   3. Jenkinson MD, et al

   . EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol 2021;23:1821–34 doi:10.1093/neuonc/noab150 pmid:34181733

   CrossRefPubMed
6. 6.↵
   1. Louis DN,
   2. Perry A,
   3. Wesseling P, et al

   . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23:1231–51 doi:10.1093/neuonc/noab106 pmid:34185076

   CrossRefPubMed
7. 7.↵
   1. Buerki RA,
   2. Horbinski CM,
   3. Kruser T, et al

   . An overview of meningiomas. Future Oncol 2018;14:2161–77 doi:10.2217/fon-2018-0006 pmid:30084265

   CrossRefPubMed
8. 8.↵
   1. Hanna C,
   2. Willman M,
   3. Cole D, et al

   . Review of meningioma diagnosis and management. Egyptian Journal of Neurosurgery 2023;38:16 doi:10.1186/s41984-023-00195-z

   CrossRef
9. 9.↵
   1. Huang RY,
   2. Bi WL,
   3. Griffith B, et al

   . Imaging and diagnostic advances for intracranial meningiomas. Neuro Oncol 2019;21:i44–61 doi:10.1093/neuonc/noy143 pmid:30649491

   CrossRefPubMed
10. 10.↵
    1. Ogasawara C,
    2. Philbrick BD,
    3. Adamson DC

    . Meningioma: a review of epidemiology, pathology, diagnosis, treatment, and future directions. Biomedicines 2021;9:319 doi:10.3390/biomedicines9030319 pmid:33801089

    CrossRefPubMed
11. 11.↵
    1. Sandalcioglu IE,
    2. Hunold A,
    3. Müller O, et al

    . Spinal meningiomas: critical review of 131 surgically treated patients. Eur Spine J 2008;17:1035–41 doi:10.1007/s00586-008-0685-y pmid:18481118

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Hohenberger C,
    2. Hau P,
    3. Schebesch K-M, et al

    . Spinal meningiomas. Neurooncol Adv 2023;5:i112–21 doi:10.1093/noajnl/vdad013 pmid:37287574

    CrossRefPubMed
13. 13.↵
    1. Kerr K,
    2. Qualmann K,
    3. Esquenazi Y, et al

    . Familial syndromes involving meningiomas provide mechanistic insight into sporadic disease. Neurosurgery 2018;83:1107–18 doi:10.1093/neuros/nyy121 pmid:29660026

    CrossRefPubMed
14. 14.↵
    1. Fountain DM,
    2. Smith MJ,
    3. O’Leary C, et al

    . The spatial phenotype of genotypically distinct meningiomas demonstrate potential implications of the embryology of the meninges. Oncogene 2021;40:875–84 doi:10.1038/s41388-020-01568-6 pmid:33262459

    CrossRefPubMed
15. 15.↵
    1. Clark VE,
    2. Erson-Omay EZ,
    3. Serin A, et al

    . Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 2013;339:1077–80 doi:10.1126/science.1233009 pmid:23348505

    Abstract/FREE Full Text
16. 16.↵
    1. Williams SR,
    2. Juratli TA,
    3. Castro BA, et al

    . Genomic analysis of posterior fossa meningioma demonstrates frequent AKT1 E17K mutations in foramen magnum meningiomas. J Neurol Surg B Skull Base 2019;80:562–67 doi:10.1055/s-0038-1676821 pmid:31750041

    CrossRefPubMed
17. 17.↵
    1. Strickland MR,
    2. Gill CM,
    3. Nayyar N, et al

    . Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas. J Neurosurg 2017;127:438–44 doi:10.3171/2016.8.JNS161076 pmid:27885953

    CrossRefPubMed
18. 18.↵
    1. Abedalthagafi M,
    2. Bi WL,
    3. Aizer AA, et al

    . Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol 2016;18:649–55 doi:10.1093/neuonc/nov316 pmid:26826201

    CrossRefPubMed
19. 19.↵
    1. Brastianos PK,
    2. Horowitz PM,
    3. Santagata S, et al

    . Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 2013;45:285–89 doi:10.1038/ng.2526 pmid:23334667

    CrossRefPubMed
20. 20.↵
    1. Goutagny S,
    2. Kalamarides M

    . Meningiomas and neurofibromatosis. J Neurooncol 2010;99:341–47 doi:10.1007/s11060-010-0339-x pmid:20714782

    CrossRefPubMed
21. 21.↵
    1. Zadeh G,
    2. Goldbrunner R,
    3. Krischek B,
    4. Nassiri F

    1. Raghunathan A,
    2. Giannini C

    . Histopathology of Meningiomas. In Biological and Clinical Landscape of Meningiomas; Zadeh G, Goldbrunner R, Krischek B, Nassiri F, eds. Springer International Publishing: Cham, Switzerland. 2023;35–45
22. 22.↵
    1. Dalle Ore CL,
    2. Magill ST,
    3. Yen AJ, et al

    . Meningioma metastases: incidence and proposed screening paradigm. J Neurosurg 2019;132:1447–55 doi:10.3171/2019.1.JNS181771 pmid:30952122

    CrossRefPubMed
23. 23.↵
    1. Brastianos PK,
    2. Galanis E,
    3. Butowski N, et al

    . Advances in multidisciplinary therapy for meningiomas. Neuro Oncol 2019;21:i18–31 doi:10.1093/neuonc/noy136 pmid:30649489

    CrossRefPubMed
24. 24.↵
    1. Maggio I,
    2. Franceschi E,
    3. Tosoni A, et al

    . Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas. CNS Oncol 2021;10:CNS72 doi:10.2217/cns-2021-0003 pmid:34015955

    CrossRefPubMed
25. 25.↵
    1. Halabi R,
    2. Dakroub F,
    3. Haider MZ, et al

    . Unveiling a biomarker signature of meningioma: the need for a panel of genomic, epigenetic, proteomic, and RNA biomarkers to advance diagnosis and prognosis. Cancers (Basel) 2023;15:5339 doi:10.3390/cancers15225339 pmid:38001599

    CrossRefPubMed
26. 26.↵
    1. Vaubel RA,
    2. Chen SG,
    3. Raleigh DR, et al

    . Meningiomas with rhabdoid features lacking other histologic features of malignancy: a study of 44 cases and review of the literature. J Neuropathol Exp Neurol 2016;75:44–52 doi:10.1093/jnen/nlv006 pmid:26705409

    CrossRefPubMed
27. 27.↵
    1. Sahm F,
    2. Schrimpf D,
    3. Stichel D, et al

    . DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. Lancet Oncol 2017;18:682–94 doi:10.1016/S1470-2045(17)30155-9 pmid:28314689

    CrossRefPubMed
28. 28.↵
    1. Hielscher T,
    2. Sill M,
    3. Sievers P, et al

    . Clinical implementation of integrated molecular-morphologic risk prediction for meningioma. Brain Pathol 2023;33:e13132 doi:10.1111/bpa.13132 pmid:36377252

    CrossRefPubMed
29. 29.↵
    1. Louis DN,
    2. Perry A,
    3. Reifenberger G, et al

    . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016;131:803–20 doi:10.1007/s00401-016-1545-1 pmid:27157931

    CrossRefPubMed
30. 30.↵
    1. Menke JR,
    2. Raleigh DR,
    3. Gown AM, et al

    . Somatostatin receptor 2a is a more sensitive diagnostic marker of meningioma than epithelial membrane antigen. Acta Neuropathol 2015;130:441–43 doi:10.1007/s00401-015-1459-3 pmid:26195322

    CrossRefPubMed
31. 31.↵
    1. Gousias K,
    2. Trakolis L,
    3. Simon M

    . Meningiomas with CNS invasion. Front Neurosci 2023;17:1189606 doi:10.3389/fnins.2023.1189606 pmid:37456997

    CrossRefPubMed
32. 32.↵
    1. Rogers C,
    2. Perry A,
    3. Pugh S, et al

    . Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539. Neuro Oncol 2015;18:545–74 doi:10.1093/neuonc/nov247 pmid:26493095

    CrossRefPubMed
33. 33.↵
    1. Deng J,
    2. Hua L,
    3. Bian L, et al

    ; Group of Neuro-Oncology, Society of Neurosurgery, Chinese Medical Associatio. Molecular diagnosis and treatment of meningiomas: an expert consensus (2022). Chin Med J (Engl) 2022;135:1894–912 doi:10.1097/CM9.0000000000002391 pmid:36179152

    CrossRefPubMed
34. 34.↵
    1. Rebchuk AD,
    2. Chaharyn BM,
    3. Alam A, et al

    . The impact of brain invasion criteria on the incidence and distribution of WHO grade 1, 2, and 3 meningiomas. Neuro Oncol 2022;24:1524–32 doi:10.1093/neuonc/noac032 pmid:35139206

    CrossRefPubMed
35. 35.↵
    1. Gauchotte G,
    2. Peyre M,
    3. Pouget C, et al

    . Prognostic value of histopathological features and loss of H3K27me3 immunolabeling in anaplastic meningioma: a multicenter retrospective study. J Neuropathol Exp Neurol 2020;79:754–62 doi:10.1093/jnen/nlaa038 pmid:32447376

    CrossRefPubMed
36. 36.↵
    1. Domingues P,
    2. González-Tablas M,
    3. Otero Á, et al

    . Genetic/molecular alterations of meningiomas and the signaling pathways targeted. Oncotarget 2015;6:10671–88 doi:10.18632/oncotarget.3870 pmid:25965831

    CrossRefPubMed
37. 37.↵
    1. Deprez RH,
    2. Bianchi AB,
    3. Groen NA, et al

    . Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas. Am J Hum Genet 1994;54:1022–29 pmid:7911002

    PubMedWeb of Science
38. 38.↵
    1. Zang KD

    . Meningioma: a cytogenetic model of a complex benign human tumor, including data on 394 karyotyped cases. Cytogenet Cell Genet 2001;93:207–20 doi:10.1159/000056986 pmid:11528114

    CrossRefPubMedWeb of Science
39. 39.↵
    1. Goutagny S,
    2. Bah AB,
    3. Henin D, et al

    . Long-term follow-up of 287 meningiomas in neurofibromatosis type 2 patients: clinical, radiological, and molecular features. Neuro Oncol 2012;14:1090–96 doi:10.1093/neuonc/nos129 pmid:22711605

    CrossRefPubMed
40. 40.↵
    1. Wang EJ,
    2. Haddad AF,
    3. Young JS, et al

    . Recent advances in the molecular prognostication of meningiomas. Front Oncol 2022;12:910199 doi:10.3389/fonc.2022.910199 pmid:36686824

    CrossRefPubMed
41. 41.↵
    1. Bachir S,
    2. Shah S,
    3. Shapiro S, et al

    . Neurofibromatosis type 2 (NF2) and the implications for vestibular schwannoma and meningioma pathogenesis. Int J Mol Sci 2021;22:690 doi:10.3390/ijms22020690 pmid:33445724

    CrossRefPubMed
42. 42.↵
    1. Mirian C,
    2. Duun-Henriksen AK,
    3. Juratli T, et al

    . Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis. J Neurol Neurosurg Psychiatry 2020;91:378–87 doi:10.1136/jnnp-2019-322257 pmid:32041819

    Abstract/FREE Full Text
43. 43.↵
    1. Maier AD,
    2. Stenman A,
    3. Svahn F, et al

    . TERT promoter mutations in primary and secondary WHO grade III meningioma. Brain Pathol 2021;31:61–69 doi:10.1111/bpa.12892 pmid:32805769

    CrossRefPubMed
44. 44.↵
    1. Juratli TA,
    2. Thiede C,
    3. Koerner MVA, et al

    . Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas. Oncotarget 2017;8:109228–37 doi:10.18632/oncotarget.22650 pmid:29312603

    CrossRefPubMed
45. 45.↵
    1. Birzu C,
    2. Peyre M,
    3. Sahm F

    . Molecular alterations in meningioma: prognostic and therapeutic perspectives. Curr Opin Oncol 2020;32:613–22 doi:10.1097/CCO.0000000000000687 pmid:32890025

    CrossRefPubMed
46. 46.↵
    1. Sievers P,
    2. Hielscher T,
    3. Schrimpf D, et al

    . CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. Acta Neuropathol 2020;140:409–13 doi:10.1007/s00401-020-02188-w pmid:32642869

    CrossRefPubMed
47. 47.↵
    1. Tosefsky K,
    2. Martin KC,
    3. Rebchuk AD, et al

    . Molecular prognostication in grade 3 meningiomas and p16/MTAP immunohistochemistry for predicting CDKN2A/B status. Neuro-oncology advances 2024;6:vdae002 doi:10.1093/noajnl/vdae002 pmid:38288091

    CrossRefPubMed
48. 48.↵
    1. Young JS,
    2. Kidwell RL,
    3. Zheng A, et al

    . CDK 4/6 inhibitors for the treatment of meningioma. Front Oncol 2022;12:931371 doi:10.3389/fonc.2022.931371 pmid:35936751

    CrossRefPubMed
49. 49.↵
    1. Williams EA,
    2. Wakimoto H,
    3. Shankar GM, et al

    . Frequent inactivating mutations of the PBAF complex gene PBRM1 in meningioma with papillary features. Acta Neuropathol 2020;140:89–93 doi:10.1007/s00401-020-02161-7 pmid:32405805

    CrossRefPubMed
50. 50.↵
    1. Shankar GM,
    2. Abedalthagafi M,
    3. Vaubel RA, et al

    . Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol 2017;19:535–45 doi:10.1093/neuonc/now235 pmid:28170043

    CrossRefPubMed
51. 51.↵
    1. Clark VE,
    2. Harmancı AS,
    3. Bai H, et al

    . Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas. Nat Genet 2016;48:1253–59 doi:10.1038/ng.3651 pmid:27548314

    CrossRefPubMed
52. 52.↵
    1. Youngblood MW,
    2. Miyagishima DF,
    3. Jin L, et al

    . Associations of meningioma molecular subgroup and tumor recurrence. Neuro Oncol 2020;23:783–94 doi:10.1093/neuonc/noaa226 pmid:33068421

    CrossRefPubMed
53. 53.↵
    1. Reuss DE,
    2. Piro RM,
    3. Jones DT, et al

    . Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. Acta Neuropathol 2013;125:351–58 doi:10.1007/s00401-013-1093-x pmid:23404370

    CrossRefPubMed
54. 54.↵
    1. Portet S,
    2. Naoufal R,
    3. Tachon G, et al

    . Histomolecular characterization of intracranial meningiomas developed in patients exposed to high-dose cyproterone acetate: an antiandrogen treatment. Neurooncol Adv 2019;1:vdz003 doi:10.1093/noajnl/vdz003 pmid:32642646

    CrossRefPubMed
55. 55.↵
    1. Peyre M,
    2. Gaillard S,
    3. de Marcellus C, et al

    . Progestin-associated shift of meningioma mutational landscape. Ann Oncol 2018;29:681–86 doi:10.1093/annonc/mdx763 pmid:29206892

    CrossRefPubMed
56. 56.↵
    1. Youngblood MW,
    2. Duran D,
    3. Montejo JD, et al

    . Correlations between genomic subgroup and clinical features in a cohort of more than 3000 meningiomas. J Neurosurg 2020;133:1345–54 doi:10.3171/2019.8.JNS191266

    CrossRefPubMed
57. 57.↵
    1. Shoshan Y,
    2. Chernova O,
    3. Juen SS, et al

    . Radiation-induced meningioma: a distinct molecular genetic pattern? J Neuropathol Exp Neurol 2000;59:614–20 doi:10.1093/jnen/59.7.614 pmid:10901233

    CrossRefPubMed
58. 58.↵
    1. Nassiri F,
    2. Mamatjan Y,
    3. Suppiah S, et al

    ; International Consortium on Meningiomas. DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. Neuro Oncol 2019;21:901–10 doi:10.1093/neuonc/noz061 pmid:31158293

    CrossRefPubMed
59. 59.↵
    1. Nassiri F,
    2. Wang JZ,
    3. Singh O, et al

    ; International Consortium on Meningiomas. Loss of H3K27me3 in meningiomas. Neuro Oncol 2021;23:1282–91 doi:10.1093/neuonc/noab036 pmid:33970242

    CrossRefPubMed
60. 60.↵
    1. Behling F,
    2. Paßlack P,
    3. Fodi CK, et al

    . Loss of H3K27me3 in meningiomas: an independent marker for CNS WHO grade 2? Neurooncol Adv 2023;5:vdad112 doi:10.1093/noajnl/vdad112 pmid:37727848

    CrossRefPubMed
61. 61.↵
    1. Cello G,
    2. Patel RV,
    3. McMahon JT, et al

    . Impact of H3K27 trimethylation loss in meningiomas: a meta-analysis. Acta Neuropathol Commun 2023;11:122 doi:10.1186/s40478-023-01615-9 pmid:37491289

    CrossRefPubMed
62. 62.↵
    1. Marastoni E,
    2. Barresi V

    . Meningioma grading beyond histopathology: relevance of epigenetic and genetic features to predict clinical outcome. Cancers (Basel) 2023;15:2945 doi:10.3390/cancers15112945 pmid:37296907

    CrossRefPubMed
63. 63.↵
    1. Bi WL,
    2. Greenwald NF,
    3. Abedalthagafi M, et al

    . Genomic landscape of high-grade meningiomas. NPJ Genom Med 2017;2:26 doi:10.1038/s41525-017-0023-6 pmid:29263836

    CrossRefPubMed
64. 64.↵
    1. Smith MJ,
    2. O'Sullivan J,
    3. Bhaskar SS, et al

    . Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. Nat Genet 2013;45:295–98 doi:10.1038/ng.2552 pmid:23377182

    CrossRefPubMed
65. 65.↵
    1. Smith MJ,
    2. Wallace AJ,
    3. Bennett C, et al

    . Germline SMARCE1 mutations predispose to both spinal and cranial clear cell meningiomas. J Pathol 2014;234:436–40 doi:10.1002/path.4427 pmid:25143307

    CrossRefPubMed
66. 66.↵
    1. Takase H,
    2. Yamamoto T

    . Bone invasive meningioma: recent advances and therapeutic perspectives. Front Oncol 2022;12:895374 doi:10.3389/fonc.2022.895374 pmid:35847854

    CrossRefPubMed
67. 67.↵
    1. Spille DC,
    2. Sporns PB,
    3. Heß K, et al

    . Prediction of high-grade histology and recurrence in meningiomas using routine preoperative magnetic resonance imaging: a systematic review. World Neurosurg 2019;128:174–81 doi:10.1016/j.wneu.2019.05.017 pmid:31082555

    CrossRefPubMed
68. 68.↵
    1. Osawa T,
    2. Tosaka M,
    3. Nagaishi M, et al

    . Factors affecting peritumoral brain edema in meningioma: special histological subtypes with prominently extensive edema. J Neurooncol 2013;111:49–57 doi:10.1007/s11060-012-0989-y pmid:23104516

    CrossRefPubMed
69. 69.↵
    1. El Farissi MA,
    2. Dahamou M,
    3. Bakkar N, et al

    . Atypical radiological aspect of meningioma: Web-like enhancement. Radiol Case Rep 2023;18:2796–99 doi:10.1016/j.radcr.2023.05.029 pmid:37388260

    CrossRefPubMed
70. 70.↵
    1. Lyndon D,
    2. Lansley JA,
    3. Evanson J, et al

    . Dural masses: meningiomas and their mimics. Insights Imaging 2019;10:11 doi:10.1186/s13244-019-0697-7 pmid:30725238

    CrossRefPubMed
71. 71.↵
    1. Starr CJ,
    2. Cha S

    . Meningioma mimics: five key imaging features to differentiate them from meningiomas. Clin Radiol 2017;72:722–28 doi:10.1016/j.crad.2017.05.002 pmid:28554578

    CrossRefPubMed
72. 72.↵
    1. Ghosal N,
    2. Dadlani R,
    3. Gupta K, et al

    . A clinicopathological study of diagnostically challenging meningioma mimics. J Neurooncol 2012;106:339–52 doi:10.1007/s11060-011-0669-3 pmid:21811893

    CrossRefPubMed
73. 73.↵
    1. Nagai Yamaki V,
    2. de Souza Godoy LF,
    3. Alencar Bandeira G, et al

    . Dural-based lesions: is it a meningioma? Neuroradiology 2021;63:1215–25 doi:10.1007/s00234-021-02632-y

    CrossRefPubMed
74. 74.↵
    1. Coroller TP,
    2. Bi WL,
    3. Huynh E, et al

    . Radiographic prediction of meningioma grade by semantic and radiomic features. PLoS One 2017;12:e0187908 doi:10.1371/journal.pone.0187908 pmid:29145421

    CrossRefPubMed
75. 75.↵
    1. Morin O,
    2. Chen WC,
    3. Nassiri F, et al

    . Integrated models incorporating radiologic and radiomic features predict meningioma grade, local failure, and overall survival. Neurooncol Adv 2019;1:vdz011 doi:10.1093/noajnl/vdz011 pmid:31608329

    CrossRefPubMed
76. 76.↵
    1. Adeli A,
    2. Hess K,
    3. Mawrin C, et al

    . Prediction of brain invasion in patients with meningiomas using preoperative magnetic resonance imaging. Oncotarget 2018;9:35974–82 doi:10.18632/oncotarget.26313 pmid:30542511

    CrossRefPubMed
77. 77.↵
    1. Amano T,
    2. Nakamizo A,
    3. Murata H, et al

    . Preoperative prediction of intracranial meningioma grade using conventional CT and MRI. Cureus 2022;14:e21610 doi:10.7759/cureus.21610 pmid:35228967

    CrossRefPubMed
78. 78.↵
    1. Tsai YT,
    2. Hung KC,
    3. Shih YJ, et al

    . Preoperative apparent diffusion coefficient values for differentiation between low and high grade meningiomas: an updated systematic review and meta-analysis. Diagnostics (Basel) 2022;12:2945 doi:10.3390/diagnostics12030630 pmid:35328183

    CrossRefPubMed
79. 79.↵
    1. Hale AT,
    2. Wang L,
    3. Strother MK, et al

    . Differentiating meningioma grade by imaging features on magnetic resonance imaging. J Clin Neurosci 2018;48:71–75 doi:10.1016/j.jocn.2017.11.013 pmid:29174756

    CrossRefPubMed
80. 80.↵
    1. Aslan K,
    2. Gunbey HP,
    3. Tomak L, et al

    . The diagnostic value of using combined MR diffusion tensor imaging parameters to differentiate between low- and high-grade meningioma. Br J Radiol 2018;91:20180088 doi:10.1259/bjr.20180088 pmid:29770735

    CrossRefPubMed
81. 81.↵
    1. Yue Q,
    2. Isobe T,
    3. Shibata Y, et al

    . New observations concerning the interpretation of magnetic resonance spectroscopy of meningioma. Eur Radiol 2008;18:2901–11 doi:10.1007/s00330-008-1079-6 pmid:18641997

    CrossRefPubMed
82. 82.↵
    1. Lee JW,
    2. Kang KW,
    3. Park SH, et al

    . 18F-FDG PET in the assessment of tumor grade and prediction of tumor recurrence in intracranial meningioma. Eur J Nucl Med Mol Imaging 2009;36:1574–82 doi:10.1007/s00259-009-1133-x pmid:19377904

    CrossRefPubMed
83. 83.↵
    1. Ivanidze J,
    2. Roytman M,
    3. Lin E, et al

    . Gallium-68 DOTATATE PET in the evaluation of intracranial meningiomas. J Neuroimaging 2019;29:650–56 doi:10.1111/jon.12632 pmid:31107591

    CrossRefPubMed
84. 84.↵
    1. Ivanidze J,
    2. Chang SJ,
    3. Haghdel A, et al

    . [Ga68] DOTATATE PET/MRI-guided radiosurgical treatment planning and response assessment in meningiomas. Neuro Oncol 2024 Mar 30. [Epub ahead of print] doi:10.1093/neuonc/noae067 pmid:38553990

    CrossRefPubMed
85. 85.↵
    1. Perlow HK,
    2. Nalin AP,
    3. Handley D, et al

    . A prospective registry study of (68)Ga-DOTATATE PET/CT incorporation into treatment planning of intracranial meningiomas. Int J Radiat Oncol Biol Phys 2024;118:979–85 doi:10.1016/j.ijrobp.2023.10.014 pmid:37871886

    CrossRefPubMed
86. 86.↵
    1. Kim SH,
    2. Roytman M,
    3. Madera G, et al

    . Evaluating diagnostic accuracy and determining optimal diagnostic thresholds of different approaches to [⁶⁸Ga]-DOTATATE PET/MRI analysis in patients with meningioma. Sci Rep 2022;12:9256 doi:10.1038/s41598-022-13467-9 pmid:35661809

    CrossRefPubMed
87. 87.↵
    1. Sommerauer M,
    2. Burkhardt J-K,
    3. Frontzek K, et al

    . ⁶⁸Gallium-DOTATATE PET in meningioma: a reliable predictor of tumor growth rate? Neuro Oncol 2016;18:1021–27 doi:10.1093/neuonc/now001 pmid:26865086

    CrossRefPubMed
88. 88.↵
    1. Afshar-Oromieh A,
    2. Giesel FL,
    3. Linhart HG, et al

    . Detection of cranial meningiomas: comparison of ⁶⁸Ga-DOTATOC PET/CT and contrast-enhanced MRI. Eur J Nucl Med Mol Imaging 2012;39:1409–15 doi:10.1007/s00259-012-2155-3 pmid:22669255

    CrossRefPubMed
89. 89.↵
    1. Kunz WG,
    2. Jungblut LM,
    3. Kazmierczak PM, et al

    . Improved detection of transosseous meningiomas using ⁶⁸Ga-DOTATATE PET/CT compared with contrast-enhanced MRI. J Nucl Med 2017;58:1580–87 doi:10.2967/jnumed.117.191932 pmid:28450556

    Abstract/FREE Full Text
90. 90.↵
    1. Teske N,
    2. Biczok A,
    3. Quach S, et al

    . Postoperative [(⁶⁸Ga]Ga-DOTA-TATE PET/CT imaging is prognostic for progression-free survival in meningioma WHO grade 1. Eur J Nucl Med Mol Imaging 2023;51:206–17 doi:10.1007/s00259-023-06400-3 pmid:37642702

    CrossRefPubMed
91. 91.↵
    1. Gaito S,
    2. Goyal L,
    3. Rieu R, et al

    . Radiotherapy intensification for atypical and malignant meningiomas: a systematic review. Neurooncol Pract 2023;11:115–24 doi:10.1093/nop/npad077 pmid:38496911

    CrossRefPubMed
92. 92.↵
    1. Aizer AA,
    2. Bi WL,
    3. Kandola MS, et al

    . Extent of resection and overall survival for patients with atypical and malignant meningioma. Cancer 2015;121:4376–81 doi:10.1002/cncr.29639 pmid:26308667

    CrossRefPubMed
93. 93.↵
    1. Schartz D,
    2. Furst T,
    3. Ellens N, et al

    . Preoperative embolization of meningiomas facilitates reduced surgical complications and improved clinical outcomes: a meta-analysis of matched cohort studies. Clin Neuroradiol 2023;33:755–62 doi:10.1007/s00062-023-01272-4 pmid:36854814

    CrossRefPubMed
94. 94.↵
    1. Gagliardi F,
    2. De Domenico P,
    3. Snider S, et al

    . Efficacy of radiotherapy and stereotactic radiosurgery as adjuvant or salvage treatment in atypical and anaplastic (WHO grade II and III) meningiomas: a systematic review and meta-analysis. Neurosurg Rev 2023;46:71 doi:10.1007/s10143-023-01969-7 pmid:36928326

    CrossRefPubMed
95. 95.↵
    1. Gendreau JL,
    2. Sheaffer K,
    3. Macdonald N, et al

    . Stereotactic radiosurgery for cerebellopontine meningiomas: a systematic review and meta-analysis. Br J Neurosurg 2023;37:199–205 doi:10.1080/02688697.2022.2064425 pmid:35475408

    CrossRefPubMed
96. 96.↵
    1. Lemée JM,
    2. Corniola MV,
    3. Meling TR

    . Benefits of re-do surgery for recurrent intracranial meningiomas. Sci Rep 2020;10:303 doi:10.1038/s41598-019-57254-5 pmid:31941981

    CrossRefPubMed
97. 97.↵
    1. Graillon T,
    2. Romano D,
    3. Defilles C, et al

    . Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review. J Neurosurg 2017;127:660–69 doi:10.3171/2016.8.JNS16995 pmid:27982767

    CrossRefPubMed
98. 98.↵
    1. Marincek N,
    2. Radojewski P,
    3. Dumont RA, et al

    . Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a Phase II clinical trial. J Nucl Med 2015;56:171–76 doi:10.2967/jnumed.114.147256 pmid:25593116

    Abstract/FREE Full Text
99. 99.↵
    1. Maggio I,
    2. Franceschi E,
    3. Di Nunno V, et al

    . Discovering the molecular landscape of meningioma: the struggle to find new therapeutic targets. Diagnostics 2021;11:1852 doi:10.3390/diagnostics11101852 pmid:34679551

    CrossRefPubMed
100. 100.↵
     1. Graillon T,
     2. Sanson M,
     3. Campello C, et al

     . Everolimus and octreotide for patients with recurrent meningioma: results from the phase II CEVOREM trial. Clin Cancer Res 2020;26:552–557 doi:10.1158/1078-0432.CCR-19-2109 pmid:31969329

     Abstract/FREE Full Text
101. 101.↵
     1. Shih KC,
     2. Chowdhary S,
     3. Rosenblatt P, et al

     . A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma. J Neurooncol 2016;129:281–288 doi:10.1007/s11060-016-2172-3 pmid:27311730

     CrossRefPubMed
102. 102.↵
     1. Salgues B,
     2. Graillon T,
     3. Horowitz T, et al

     . Somatostatin receptor theranostics for refractory meningiomas. Curr Oncol 2022;29:5550–5565 doi:10.3390/curroncol29080438 pmid:36005176

     CrossRefPubMed